Education
About Us
Working with TipRanks
Follow Us
Cipher Pharmaceuticals (TSE:CPH)
TSX:CPH
CPH Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$7.90 - C$19.69
Previous CloseN/A
Volume17.82K
Average Volume (3M)33.56K
Market Cap
$315.56M
Enterprise ValueC$425.81M
Total Cash (Recent Filing)$10.36M
Total Debt (Recent Filing)$17.57M
Price to Earnings (P/E)19.1
Beta-0.43
Next Earnings
May 08, 2025EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.64
Shares Outstanding25,613,605
10 Day Avg. Volume35,712
30 Day Avg. Volume33,561
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.98
Price to Cash Flow (P/CF)6.60
P/FCF Ratio6.40
Enterprise Value/Market Cap1.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit24.91
Enterprise Value/Ebitda33.87
Forecast
1Y Price Target
C$16.99Price Target Upside37.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Cipher Pharmaceuticals News
PremiumCompany Announcements
Cipher Pharmaceuticals Reports Robust Q4 2024 Growth
PremiumCompany Announcements
Cipher Pharmaceuticals Reports Strong 2024 Financial Growth
PremiumCompany Announcements
Cipher Pharmaceuticals to Announce Q4 & Fiscal 2024 Results
PremiumCompany Announcements
Cipher Pharmaceuticals Faces Setback but Eyes Growth
PremiumCompany Announcements
Cipher Pharmaceuticals Q3 2024 Results: Growth and Acquisitions---
Options Prices
Currently, No data available
---
Ownership Overview
1.44% Insiders
0.91%
Mutual Funds
0.72% Other Institutional Investors
96.79% Public Companies and
Individual Investors
CPH FAQ
What was Cipher Pharmaceuticals’s price range in the past 12 months?
Cipher Pharmaceuticals lowest stock price was C$7.90 and its highest was C$19.69 in the past 12 months.
What is Cipher Pharmaceuticals’s market cap?
Cipher Pharmaceuticals’s market cap is $315.56M.
When is Cipher Pharmaceuticals’s upcoming earnings report date?
Cipher Pharmaceuticals’s upcoming earnings report date is May 08, 2025 which is in 42 days.
How were Cipher Pharmaceuticals’s earnings last quarter?
Cipher Pharmaceuticals released its earnings results on Mar 18, 2025. The company reported C$0.186 earnings per share for the quarter, missing the consensus estimate of C$0.271 by -C$0.086.
Is Cipher Pharmaceuticals overvalued?
According to Wall Street analysts Cipher Pharmaceuticals’s price is currently Undervalued.
Does Cipher Pharmaceuticals pay dividends?
Cipher Pharmaceuticals does not currently pay dividends.
What is Cipher Pharmaceuticals’s EPS estimate?
Cipher Pharmaceuticals’s EPS estimate is 0.21.
How many shares outstanding does Cipher Pharmaceuticals have?
Cipher Pharmaceuticals has 25,613,605 shares outstanding.
What happened to Cipher Pharmaceuticals’s price movement after its last earnings report?
Cipher Pharmaceuticals reported an EPS of C$0.186 in its last earnings report, missing expectations of C$0.271. Following the earnings report the stock price went up 12.27%.
Which hedge fund is a major shareholder of Cipher Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:CPH
---
Cipher Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$16.99 (37.89% Upside)
C$16.99 (37.89% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.44%
12-Months-Change
Fundamentals
Return on Equity
12.63%
Trailing 12-Months
Asset Growth
88.90%
Trailing 12-Months
Company Description
Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
---
CPH Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reveals significant revenue and market share growth, particularly from Epuris and the newly integrated Natroba business. Despite these achievements, challenges such as declining licensing revenue and increased SG&A expenses were notable. The positive revenue growth and strategic business developments outweigh the lowlights, suggesting an optimistic outlook.Read More>---
CPH Stock 12 Month Forecast
Average Price Target
C$16.99
▲(37.89% Upside)
Technical Analysis
Best Analysts Covering CPH
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
+16.17%
reiterated a buy rating 3 days ago
Copying Justin Keywood's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +16.17% per trade.
---